LMO3

Across TCGA pan-cancer cohorts, LMO3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LMO3 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LMO3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMO3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

UCEC, GBM, and LUAD are the cancer types where LMO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	0.383	0.953	.032	8	view →
GBM	OS	Median	All	0.700	0.321	.024	4	view →
LUAD	OS	Median	All	0.492	0.873	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LMO3–UCEC (DFS)

Open the UCEC breakdown →